Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
Home » Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development

GH AMEA on Social MediaGuardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
GH AMEA

Guardant Health, Inc. addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM™ platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients.

Click on the press release link below to find out more.

https://lnkd.in/gWSyhD5

Message us